Will Antibody Drug Conjugates (ADCs) Cure Bladder Cancer?

At Uromigos Live 2024, a bladder cancer panel moderated by Dr. Tom Powles and including Andrea Apolo, MD; Shilpa Gupta, MD; Kala Sridhar, MD; and Petros Grivas, MD, PhD, focused on the use of ADCs for the treatment of bladder cancer, analyzing the response rates of various ADC treatments and their related side effects. In the first part of this panel, the use and impact of enfortumab vedotin in the bladder cancer landscape was discussed. The panelists also break down the EV-103 study and EV-302.

In the third part of this panel, the use of HER2 ADCs in bladder cancer is explored, including various trials on disitamab vedotin and trastuzumab deruxtecan.

In the second segment of this panel, the use of sacituzumab govitecan monotherapy and in combination with other treatments is discussed.

During the fourth segment of this panel, novel ADCs including HER3, Nectin-4, and BT8009 are analyzed.

During the final part of this panel, novel ADCs are explored and analyzed for use in different settings and patient populations.